$TMO

Shafer Michael D sold $15.3M of TMO

Shafer Michael D (Executive Vice President) sold 25,500 shares of THERMO FISHER SCIENTIFIC INC. (TMO) at $600.00 ($15.30M total) across 2 trades on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Shafer Michael D
Published Aug 13, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMO
Neutral
medium confidence
Mentioned
$TMO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMONeutralLow
01

Why it matters

The newest disclosed fact is the size, price, and timing of the insider open-market sale under a pre-arranged 10b5-1 plan.

02

Market read

This provides a concrete, time-stamped insider selling datapoint for TMO, but it is pre-arranged and does not include new fundamentals.

03

What to watch

Traders may over-weight insider sales; the filing lacks context on total holdings, tax planning, or whether other executives are selling/buying around the same window.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-13, transaction dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for Thermo Fisher Scientific, reported by an executive vice president.

Company-level read

Ticker impact

$TMONeutralMedium confidence
Context

Thermo Fisher executive Michael D. Shafer sold $15.3M of TMO shares via a Rule 10b5-1 plan on 2026-08-11 at $600/share.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader tape and any additional disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit Rule 10b5-1 pre-arrangement, reducing the signal of new negative information. The disclosed fact is time-stamped and tradable for positioning around sentiment, but it does not include earnings, guidance, or operational changes.

Market effects

No direct sector read-through; this is company-specific insider selling with no operational or regulatory trigger described.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a Rule 10b5-1 plan, it may reflect routine liquidity/compensation rather than bearish expectations.

Key entities

  • THERMO FISHER SCIENTIFIC INC.

    Subject of the Form 4 insider transaction disclosure.

  • Shafer Michael D

    Executive Vice President who sold 25,500 shares at $600/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QNTMMed

Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis

Quantum BioPharma (QNTM) has signed a contract with Thermo Fisher Scientific to implement its Phase 2 clinical trial for Lucid-MS, a treatment for multiple sclerosis. The trial will evaluate the drug's efficacy, safety, and tolerability. Quantum BioPharma received FDA clearance to proceed with the study. The multiple sclerosis market is projected to exceed $38 billion by 2030, according to Grand View Research.

$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

$TMOMed

TMO Stock Could Gain Following the Launch of EMPAD G2 Detector

Thermo Fisher Scientific (TMO) launched the EMPAD G2 detector for advanced materials analysis, aiming to boost its Analytical Instruments segment. Shares dipped 0.8% post-announcement. The company has a $233.20B market cap, 4% earnings yield, and a track record of beating earnings estimates. The global 4D STEM market, where EMPAD G2 operates, is projected to grow at 6.6% CAGR through 2031, according to QYResearch.